RecruitingPhase 3NCT06056297
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Sponsor: X4 Pharmaceuticals
Dallas, TX · Fort Worth, TX · Houston, TX · +19 more sites